SYNDAX PHARMACEUTICALS INC (SNDX)

Company Profile

Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in the development of cancer therapies. The company is headquartered in Waltham, Massachusetts and currently employs 107 full-time employees. The company went IPO on 2016-03-03. The Company’s lead product candidates include SNDX-5613 (revumenib) and SNDX-6352 (axatilimab). The company is focused on developing revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, also known as mixed lineage leukemia rearranged (MLLr), acute leukemias including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML), and nucleophosmin 1 (NPM1) mutant AML. Its axatilimab, is a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor in chronic graft-versus-host disease (cGVHD), as well as idiopathic pulmonary fibrosis (IPF). Its products candidate also includes entinostat, an oral, small molecule and Class I histone deacetylases (HDAC) inhibitor that has direct effects on both cancer cells and immune regulatory cells.

Company Info

SYNDAX PHARMACEUTICALS INC

Suite 650, 460 Totten Pond Road

Waltham MASSACHUSETTS 02451

P: 17814191400

CEO: Briggs W. Morrison

Employees: 107

Website: https://syndax.com/